Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 6/20 | 0.86 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | DHODH | Q02127 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL290844 | 0.93 | PDE5A (1.00) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL29831744 | 0.91 | PDE5A (0.71) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL289230 | 0.91 | PDE5A (0.71) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL2681053 | 0.90 | PDE5A (0.88) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL290788 | 0.90 | PDE5A (0.91) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL29832145 | 0.90 | PDE5A (0.91) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| Methane SCHEMBL4540930 | 0.90 | PDE5A (0.86) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL6068573 | 0.89 | PDE5A (0.84) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL291630 | 0.88 | PDE5A (0.89) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL6068214 | 0.87 | PDE5A (0.88) | PDE5AMAPTKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158247-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2016-06-09 | — | — | US | disclosed |
| US-7087614-B2 | Pyrimidine inhibitors of phosphodiesterase (PDE) 7 | BRISTOL-MYERS SQUIBB CO. (US) | 2006-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158247-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | PDE5A 8/4885MAPT 3149/4885KDM4E 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.